CD4-dependent and CD4-independent HIV-2: Consequences for neutralization

AIDS

Volumn 17, Issue 3, 2003, Pages 291-300

  Thomas, Elaine R ^a   Shotton, Christine ^b   Weiss, Robin A ^a   Clapham, Paul R ^a,c   McKnight, Áine ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antibodies; Envelope proteins; HIV 2; Neutralization; Virus cell interaction

Indexed keywords

CD4 ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; MONOMER; NEUTRALIZING ANTIBODY; OLIGOMER;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS ISOLATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-2; HUMANS; NEUTRALIZATION TESTS; VIRAL LOAD;

EID: 0037436187     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200302140-00002     Document Type: Article

References (80)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
2. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira Mo, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986, 233:343-346.
3. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224:500-503.
4. Schim van der Loeff M, Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS 1999, 13:S69-S84.
5. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265:1587-1590.
6. Bjorling E, Scarlatti G, von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, et al. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993, 193:528-530.
7. Fenyo EM, Putkonen P. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. Immunol Lett 1996, 51:95-99.
8. Bottiger B, Karlsson A, Andreasson PA, Naucler A, Costa CM, Norrby E, et al. Envelope cross-reactivity between human immunodeficiency virus types I and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site. J Virol 1990, 64:3492-3499.
9. Weiss RA, Clapham PR, JN Weber, D Whitby, RS Tedder, T O'Connor, et al. HIV-2 antisera cross-neutralize HIV-1. AIDS 1988, 2:95-100.
10. Clapham PR, Reeves JD, Simmons G, Dejucq N, Hibbitts S, McKnight A. HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Mol Membr Biol 1999, 16:49-55.
11. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, et al. Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 2000, 97:9026-9031.
12. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
13. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280:1949-1953.
14. Thali M, Moore JP, Furman C, Chades M, Ho DD, Robinson J, et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993, 67:3978-3988.
15. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995, 69:5723-5733.
16. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
17. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
18. Burton DR, Barbas, 3rd CF, Persson MA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type I human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991, 88:10134-10137.
19. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
20. McKeating JA, Bennett J, Zolla-Pazner S, Schutten M, Ashelford S, Brown AL, et al. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J Virol 1993, 67:5216-5225.
21. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995, 69:101-109.
22. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991, 146:4325-4332.
23. Roben P, Moore JP, Thali M, Sodroski J, Barbas 3rd CF, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68:4821-4828.
24. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, PM Rudd, et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 2001, 293:1155-1159.
25. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995, 69:6609-6617.
26. Chamat S, Nara P, Berquist L, Whalley A, Morrow WJ, Kohler H, et al. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. J Immunol 1992, 149:649-654.
27. Hariharan K, Nara PL, Caralli VM, Norton FL, Haigwood N, Kang CY. Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals. J Virol 1993, 67:953-960.
28. Moore JP, Ho DD. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993, 67:863-875.
29. Steimer KS, Scandella CJ, Skiles PV, Haigwood NL. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 1991, 254:105-108.
30. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000, 74:326-333.
31. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998, 72:4694-4703.
32. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647.
33. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002, 76:7293-7305.
34. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002, 76:7306-7321.
35. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
36. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6:200-206.
37. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997, 3:1389-1393.
38. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of macaques against pathogenic simian/ human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
39. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
40. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75:8340-8347.
41. D'Souza MP, Livnat D, Bradac JA, Bridges SH. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J Infect Dis 1997, 175:1056-1062.
42. Clapham PR, McKnight A, Weiss RA. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol 1992, 66:3531-3537.
43. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996, 87:745-756.
44. Reeves JD, Hibbitts S, Simmons G, McKnight A, Azevedo-Pereira JM, Moniz-Pereira J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999, 73:7795-7804.
45. Reeves JD, Schulz TF. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. J Virol 1997, 71:1453-1465.
46. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348.
47. Clapham PR, Blanc D, Weiss RA. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology 1991, 181:703-715.
48. McKnight A, Clapham PR, Weiss RA. HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages. Virology 1994, 201:8-18.
49. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36:59-74.
50. Soda Y, Shimizu N, Jinno A, Liu HY, Kanbe K, Kitamura T, et al. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 1999, 258:313-321.
51. Foley GE, Lazarus S, Farber B, Geren Uzmain B, Boone BA, McCarthy RE. Continuous culture of human lymphoblasts from peripheral blood from a child with acute leukemia. Cancer 1965, 18:522-529.
52. McKnight A, Griffiths DJ, Dittmar M, Clapham P, Thomas E. Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2. J Virol 2001, 75:6914-6922.
53. Keller R, Peden K, Paulous S, Montagnier L, Cordonnier A, Amino acid changes in the fourth conserved region of human immunodeficiency virus type 2 strain HIV-2ROD envelope glycoprotein modulate fusion. J Virol 1993, 67:6253-6258.
54. McKnight A, Shotton C, Cordell J, Jones I, Simmons G, Clapham PR. Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol 1996, 70:4598-4606.
55. Parren PW, Mondor I, Naniche D, Ditzel HJ, Klasse PJ, Burton DR, et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998, 72:3512-3519.
56. Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, Baleux F, et al. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 1998, 72:512-19.
57. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV- 1 envelope protein. Proc Natl Acad Sci USA 1999, 96:6359-6364.
58. Hoxie JA, LaBranche CC, Endres MJ, Turner JD, Berson JF, Doms RW, et al. CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. J Reprod Immunol 1998, 41:197-211.
59. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, et al. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999, 73:8120-8126.
60. Borsetti A, Parolin C, Ridolfi B, Sernicola L, Geraci A, Ensoli B, et al. CD4-independent infection of two CD4(-)/CCR5(-)/ CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses. J Virol 2000, 74:6689-6694.
61. Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee B, Rucker J, et al. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci USA 1997, 94:14742-14747.
62. Liu HY, Soda Y, Shimizu N, Haraguchi Y, Jinno A, Takeuchi Y, et al. CD4-Dependent and CD4-independent utilization of coreceptors by human immunodeficiency viruses type 2 and simian immunodeficiency viruses. Virology 2000, 278:276-288.
63. Martin KA, Wyatt R, Farzan M, Choe H, Marcon L, Desjardins E, et al. CD4-independent binding of SIV gp120 to rhesus CCR5. Science 1997, 278:1470-1473.
64. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, Desrosiers RC. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on cd4. J Virol 2001, 75:3903-3915.
65. Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, Reitter J, et al. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 2002, 76:2595-2605.
66. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, et al. utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997, 71:8999-9007.
67. Kolchinsky P, Kiprilov E, Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001, 75:2041-2050.
68. Allan, JS, Strauss J, Buck DW. Enhancement of SIV infection with soluble receptor molecules. Science 1990, 247:1084-1088.
69. Zhang PF, Bouma P, Park EJ, Margalick JB, Robinson JE, Zolla-Pazner S, et al. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 2002, 76:644-655.
70. Edwards TG, Hoffman TL, Baribaud F, Wyss S, LaBranche CC, Romano J, et al. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 2001, 75:5230-5239.
71. Kolchin̄sky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 2001, 75:3435-3443.
72. Johnson WE, Morgan J, Reitter J, Puffer BA, Czajak S, Doms RW, et al. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol 2002, 76:2075-2086.
73. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995, 182:185-196.
74. Parren PW, Burton DR, Sattentau QJ. HIV-1 antibody - debris or virion? Nat Med 1997, 3:366-367.
75. Watkins BA, Buge S, Aldrich K, Davis AE, Robinson J, Reitz Jr MS, et al. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J Virol 1996, 70:8431-8437.
76. Zolla-Pazner S, O'Leary J, Burda S, Gorny MK, Kim M, Mascola J, et al. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol 1995, 69:3807-3815.
77. Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nadas A, et al. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 2000, 74:7096-7107.
78. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995, 69:39-48.
79. York J, Follis KE, Trahey M, Nyambi PN, Zolla-Pazner S, Nunberg JH. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. J Virol 2001, 75:2741-2752.
80. Morner A, Thomas JA, Bjorling E, Munson PJ, Lucas SB, McKnight A. Productive HIV-2 infection in the CNS is restricted to macrophages/microglia. submitted.